Trial Profile
A phase 2, double-blind, placebo-controlled, randomized, parallel-group, multicenter study to evaluate the efficacy and safety of 40mg/day KW-6002 (istradefylline) in subjects with restless legs syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Istradefylline (Primary)
- Indications Restless legs syndrome
- Focus Therapeutic Use
- Sponsors Kyowa Kirin Pharmaceutical Development
- 18 Nov 2005 New trial record.